Our recent work on vaccine prioritization for COVID-19 is now published in @ScienceMagazine, but this paper has evolved because of both formal and informal peer review. So while the paper is linked, here's a quick summary of the results. 🧵 1/

science.sciencemag.org/content/early/…
First, rather than reading another Twitter summary, there's a great discussion of this work in the broader context of vaccination strategies by two vaccine/modeling experts @MeaganCFitz @Alison_Galvani. Highly recommended for both theory & history. 2/

science.sciencemag.org/content/early/…
IMO there are 2 intuitive ideas in vaccine prioritization:
Intuition 1: directly protect the vulnerable.
Intuition 2: vaccinate to break transmission chains & indirectly protect vulnerable.

When intuition supports two opposing conclusions, don't use intuition—use math. 🤓 3/
We used an SEIR model with age groups by decade, and considered variation in:
* vaccine efficacy
* transmission-blocking effects
* rollout speed
* demography & contact patterns
* IFR [by age]
* existing antibodies
* vaccine hesitancy
Then, we simulated 1 year of transmission. 4/
By comparing vaccine rollouts to a no-vaccine scenario, we measured reductions in (a) mortality, (b) total infections, and (c) years of life lost.

This allowed us to see which intuition would actually save more lives: protect the vulnerable or move toward herd immunity? 5/
The left plot shows the 5 strategies we investigated. On the right, there are simulation outputs for no vaccine (dashed line) and with vaccines rolled out out at 0.2% of the population per day (grey area).

The purple line (60+) ends in fewer deaths in both columns. 6/
It would take forever to look at tons of individual plots so instead, we summarized impacts across vaccine supply levels.

Here, for any vaccine supply between 0% and 50%, in this scenario (see paper), prioritizing adults 60+ reduces mortality more than alternatives. 7/
These curves depend on the scenarios and parameters, so we created an interactive calculator using the same mathematical model as the paper.

You can explore various scenarios, countries, vaccines, and rollout speeds. ⤵️
vaxfirst.colorado.edu 8/
To build a broader understanding, it helps to be able to view a lot of simulations at once (h/t Reviewers 😎) and see which strategy was BEST to ⬇️ mortality.

For example, here are 2000 combinations of vaccine rollout speed, supply, & transmission. Purple=prioritize 60+ best. 9/
👆 notice that this plot shows that IF we could keep transmission low from here on out (low R), and IF the vaccine blocks transmission, then we might also consider prioritizing those 20-49 (teal).

But if vaccines block transmission poorly, this plot becomes all purple (60+). 10/
In the paper, we show lots of other scenario combinations, that help explore unknowns:
* How well does vaccine block transmission?
* Does efficacy hold up for older folks?
* Do results vary by country?
* How important is rollout speed?
* What add'l vax options do Taiwan, NZ have?
In general:

If the goal is to reduce mortality, prioritizing adults 60+ is the most robust way to achieve that goal across countries, vaccines, and current unknowns (transmission blocking, efficacy for older folks, etc). 12/
Finally, let's not forget that it's "vaccines AND..."

We can take other actions to save lives while we wait in the queue:
* reducing transmission by continuing to wear masks and avoiding indoor gathering,
* using rapid screening tests
* working to decrease vax hesitancy 13/
This work was driven by @bubar_kate, backed by a wonderful & generous team: @StephenKissler @mlipsitch @sarahcobey @yhgrad. Kyle Reinholt 🧙‍♂️built interactive tools. 14/14

📄 Paper: science.sciencemag.org/content/early/…
💻 Code: github.com/kbubar/vaccine…
📈 Online Tools: vaxfirst.colorado.edu

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dan Larremore

Dan Larremore Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DanLarremore

9 Dec 20
Updated preprint: Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.

Smart suggestions from formal/informal review mean that the paper still asks how demographics, contacts, vax efficacy, & seroprevalence affect prioritization by age, but now...1/
We asked whether transmission-blocking properties affect prioritization. Intuitively, as the vaccine's transmission blocking properties become worse, direct protection of adults 60+ became/remained the clear best prioritization—across countries, R0 values, & vaccine supplies. 2/
Btw—there's a nice piece by @MollyEFG & team that shows why indirect effects are critical. In the medrxiv version of their NatMed editorial, they have this figure, showing how transmission blocking effects are *extremely* valuable at pop. scale. nature.com/articles/s4159… Image
Read 12 tweets
2 Dec 20
Preprint: COVID-19 screening and surveillance are critical, but molecular tests haven't come close to meeting needs, and temperature checks fail. We modeled the epidemiological impacts of using loss of smell as a screening symptom. Here's what we found. 1/ medrxiv.org/content/10.110…
Loss of smell is an interesting screening symptom because it's highly specific to COVID, precedes most other overt symptoms, and typically lasts ~1 week. Critically, its prevalence goes from ~45% when self-reported up to ~80% when a test is used. 2/
Contrast this with fever: ~20% prevalence, not specific to COVID, and lasts 1.5 days on average. So why do we still screen for fever? You can look for it in seconds with a contactless thermometer.

Could rapid, contactless, cheap tests for anosmia, impact transmission? 3/
Read 15 tweets
28 Oct 20
Slovakia (pop 5.5M) is attempting a mass COVID-19 screening campaign using rapid antigen tests. The public health community is going to learn a lot. Here's what I'm looking for...
1/

spectator.sme.sk/c/22519165/cor…
Slovakia, like Europe, is experiencing a rapid acceleration of infections & deaths, and is starting to use curfews & lockdowns.

A pilot phase tested 140K people with rapid antigen tests, found 5.5K positives (4%).

They'll test the nation over next 2 weekends! Good idea?
2/
First, there are reasonable critiques of rapid Ag tests related to their sensitivity—do they miss too many infections?—and their specificity—do they falsely tell uninfected people that they're positive?

Re sensitivity: every broken transmission chain is a victory, BUT...
3/
Read 9 tweets
24 Oct 20
Here is my summary of an exciting new @NBA + longitudinal COVID testing paper.

Writing a thread about COVID and the NBA has been on my bucket list for some time, so today I decided to box out some time and give it a shot. 1/n

medrxiv.org/content/10.110…
Most of what we know about viral dynamics during SARS-CoV-2 infections comes from samples taken *after* symptom onset. From symptoms onward, viral loads slowly fadeaway.

What do viral loads look like between exposure and symptoms? 2/n
In this study, researchers in the NBA bubble recruited players, coaches, vendors, and others to sign up for a longitudinal study with regular COVID testing.

In other words, the researcher ran a classic pick-enroll-screen in the NBA bubble. 3/n
Read 12 tweets
1 Jul 20
How does effective viral surveillance change when (1) some people refuse to participate, and (2) sample collection errors lead to lower sensitivity, indep. of a test's limit of detection? Questions raised by @jhuber @awyllie13 & others after I posted this preprint last week.👇 1/
I love twitter+preprints precisely because of this community. In the updated preprint, we've corrected a couple typos, and created a new supplement, "Adjustments for false negatives and test refusal" which I'll quickly summarize below. 2/ medrxiv.org/content/10.110…
Previously, we estimated the impact of a policy on R by measuring the "infectiousness" the testing, relative to no testing. The formula's values correspond to the heights of bars in plots like this one. f0 is the leftmost hatched bar. ftest is the total height of a policy bar. 3/
Read 8 tweets
25 Jun 20
Preprint: Viral surveillance testing is crucial, but not all surveillance strategies are equal. We modeled the impacts of test frequency, assay limit of detection, test turnaround time, measuring impact on individuals & epidemics. Here's what we found. 1/ medrxiv.org/content/10.110…
The first finding is that limit of detection matters less than we thought. There is only short (1/2 day) window when qPCR is superior during the exp growth phase. We showed this in a simple viral load model, but any model with exp growth between Ct40 and Ct33 would confirm. 2/
So only a high-frequency testing scheme will take advantage of that short window. However, high-frequency testing schemes will have a high impact on the reproductive number, *regardless* of test LOD. ➡️ Ruling out higher LOD tests for surveillance purposes would be a mistake. 3/
Read 18 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!